Clinical efficacy of alpha1-Adrenargic Receptor Antagonist in BPH patients
Wednesday, 28 July 2010- K. Kadekawa and colleagues assessed the clinical efficacy and safety of 75 mg/day of naftopidil, an alpha1-adrenargic receptor antagonist in patients with benign prostatic hyperplasia (BPH). They published their findings in the online edition of the journal LUTS: Lower Urinary Tract Symptoms.
A total of 28 patients (mean age, 71.1 years; range, 46–86 years) with BPH were studied. Inclusion criteria were: (i) International Prostate Symptom Score (IPSS)>8; and (ii) quality of life (QOL) index >3. IPSS, QOL index, Overactive Bladder Symptom Score (OABSS), and bladder diary (urinary frequency in daytime and night-time, frequency of urinary incontinence and urgency) were evaluated before and four weeks after treatment with naftopidil at 75 mg/day.
The results showed that total IPSS and QOL index were significantly decreased after treatment. Total OABSS tended to decrease after treatment, with significant improvements in the "urgency" parameter.
From the bladder diary, urinary frequency in daytime and night-time and frequency of urgency were significantly decreased after treatment. Total IPSS and QOL index in patients with previous treatment were significantly improved after treatment, with significant improvements in the "incomplete emptying," "poor flow," and "nocturia" parameters of IPSS. One case with a mild adverse effect of dizziness was encountered.
These results suggest that administration of naftopidil at 75 mg/day was safe and effective for patients with BPH, regardless of the presence of previous treatment. This study indicates the feasibility of naftopidil at 75 mg/day as a first-line treatment for men with BPH, or a second-line treatment in cases with symptoms of incomplete emptying, poor flow and nocturia.
Source: K. Kadekawa, et al., "Clinical Efficacy of alpha1-Adrenargic Receptor Antagonist Naftopidil 75 mg/day in Patients with Benign Prostatic Hyperplasia," LUTS: Lower Urinary Tract Symptoms, (DOI) 10.1111/j.1757-5672.2010.00072.
